Regenxbio raised to Buy at RBC on pivot to Duchenne [Seeking Alpha]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Seeking Alpha
Perform, arguing that the company's foray into Duchenne muscular dystrophy should drive further upside in its stock. The upgrade comes days after the Rockville, Maryland-based biotech updated interim data from its Phase 1/2 trial for gene therapy candidate RGX-202 in children with Duchenne muscular dystrophy early this week. At the time, the company said that the treatment targeted at the C-Terminal (CT) domain of disease-causing dystrophin protein led to a significant increase in microdystrophin expression in a 12-year-old patient. Regenxbio ( RGNX ) intends to use microdystrophin expression as a surrogate endpoint in seeking accelerated approval for RGX-202 in a future biologics license application (BLA) submission. “Data is early, and quintessential question of whether retaining the CT domain can drive better outcomes remains TBD, but expression data is impressive,” RBC analyst Luca Issi wrote, raising his price target to $35 from $20. The analyst argued that the upcoming
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsPR Newswire
- Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroidal Route [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPR Newswire
RGNX
Earnings
- 2/27/24 - Miss
RGNX
Sec Filings
- 4/17/24 - Form 4
- 4/4/24 - Form ARS
- 4/4/24 - Form DEFA14A
- RGNX's page on the SEC website